BUFFALO, N.Y., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the launch of three previously disclosed sterile injectable molecules through its subsidiary Athenex Pharma Solutions (APS). APS is focused on applying pharmaceutical cGMP expertise to the 503(B) market to address hospital needs for high-quality outsourced compounding services and has launched the following products:
- Epinephrine in 250 mL Dextrose bags (2 SKUs)
- Norepinephrine in 250 mL Dextrose bags (3 SKUs)
- Phenylephrine in 250 mL Saline bags (5 SKUs)
Jeffrey Yordon, Athenex’s Chief Operating Officer and President of APS, commented, “We are pleased to provide the U.S. market with our first three 503(B) molecules. These products represent ten SKUs and are the first step in our plan to dramatically expand our portfolio and production capabilities. In the coming months we will commence with the construction of our state-of-the-art facility in Dunkirk, New York. Our strong partnership with the State of New York will allow us to provide important products to the global healthcare market and jobs to Western New York.”
Athenex’s products emphasize quality and enhance patient safety. cGMP processes are followed for each of Athenex’s products, and a Certificate of Analysis is provided for each batch of 503B products so customers are able to see measurable results from repeatable tests. Additionally, Athenex’s AccuraSEE, a proprietary and highly differentiated approach to packaging and labeling, has a unique design to give caregivers accurate information and reduce the risk of medication errors.
APS is committed to developing and providing a broad portfolio of quality injectable products compliant with the FDA Act Section 503(B). The APS product portfolio is available at www.athenexpharma.com.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites, human absorption biology and through the application of Athenex’s proprietary research and selection processes in the lab. The Company’s current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and Src Kinase Inhibition. The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which Athenex is able to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer improved patient tolerability and efficacy as compared to IV administration of the same cytotoxics. The Src Kinase Inhibition platform refers to novel small molecule compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader range of anti-cancer activity as compared to either mechanism of action alone. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York, Cranford, New Jersey, Houston, Texas, Chicago, Illinois, Hong Kong, Taipei, Taiwan, and multiple locations in Chongqing, China.
CONTACT: CONTACT: Nick Riehle Tel: +1-716-427-2952 Athenex, Inc.